Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells.

Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells.

CTLA-4 has been proposed to negatively regulate immune responses, and mice deficient for CTLA-4 expression succumb to a lymphoproliferative disorder within a few weeks after birth. This study assessed the responsiveness of CTLA-4-deficient T cells expressing a class I-restricted TCR specific for lym...

Detaylı Bibliyografya
Asıl Yazarlar:	Bachmann, M, Waterhouse, P, Speiser, D, McKall-Faienza, K, Mak, T, Ohashi, P
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	1998

Benzer Materyaller

T-cell-independent antiviral B cell responses in CD45-deficient mice.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice.
Yazar:: Waterhouse, P, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

TNF receptor p55 controls early acute graft-versus-host disease.
Yazar:: Speiser, D, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Absence of TNFRp55 influences virus-induced autoimmunity despite efficient lymphocytic infiltration.
Yazar:: McKall-Faienza, K, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy.
Yazar:: Speiser, D, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Identification of a cross-reactive self ligand in virus-mediated autoimmunity.
Yazar:: Ohteki, T, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

TNF receptor p55 mediates peripheral cytotoxic T cell deletion.
Yazar:: Speiser, D, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Functional management of an antiviral cytotoxic T-cell response.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo.
Yazar:: Speiser, D, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer
Yazar:: Maryam Jama, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Four types of Ca2+ signals in naive CD8+ cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Alloreactive cytotoxic T cells recognize minor transplantation antigens presented by major histocompatibility complex class Ib molecules.
Yazar:: Speiser, D, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Altered peptide ligands trigger perforin- rather than Fas-dependent cell lysis.
Yazar:: Bachmann, M, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
Yazar:: Jui-Ling Yu, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency
Yazar:: Lu Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies.
Yazar:: Demaria, S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Acute graft-versus-host disease without costimulation via CD28.
Yazar:: Speiser, D, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Association of CTLA-4 and IL-4 polymorphisms in viral induced liver cancer
Yazar:: Maria Shabbir, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Cytotoxic T-lymphocyte Associated Antigen-4 (CTLA-4) Polymorphism, Cancer, and Autoimmune Diseases
Yazar:: Maryam Tanhapour, ve diğerleri
Baskı/Yayın Bilgisi: (2017-10-01)

Progress in Research on Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) and Bladder Cancer
Yazar:: Wei-Ming Fang, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
Yazar:: Griffiths, E, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Role of cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression in the pathogenesis of Warthin’s tumor growth
Yazar:: Alvionika Nadyah Qotrunnada, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

CTLA4 polymorphisms and COPD.
Yazar:: Wood, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Mechanistic Elucidation and Therapeutic Improvement of Anti-CTLA-4 Therapies
Yazar:: Lax, Brianna Marie
Baskı/Yayın Bilgisi: (2023)

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
Yazar:: Erika Salvatori, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering.
Yazar:: Yu, C, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases
Yazar:: Faruk Aktürk, ve diğerleri
Baskı/Yayın Bilgisi: (2010-06-01)

Cytotoxic T lymphocyte antigen-4 (CTLA-4) A49G polymorphism and autoimmune blood diseases
Yazar:: Faruk Aktürk, ve diğerleri
Baskı/Yayın Bilgisi: (2010-06-01)

Association of Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Thyroglobulin (TG) Genetic Variants with Autoimmune Hypothyroidism.
Yazar:: Hinal Patel, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues.
Yazar:: Kei Higashikawa, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Yazar:: Sandip P. Patel, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Yazar:: Mehregan Babamohamadi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Micro-abnormalities in the retina and choroid induced by anti-CTLA4 treatment
Yazar:: Ryo Mukai, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
Yazar:: Amirali Karimi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Yazar:: Ascierto Paolo A, ve diğerleri
Baskı/Yayın Bilgisi: (2011-11-01)